[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 14
1. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E: Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat; 2010 Aug;122(3):745-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.
  • Breast cancer is the second leading cause of malignant effusions in cancer patients.
  • Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome.
  • Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer.
  • Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits.
  • Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases.
  • Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice.
  • This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

  • Genetic Alliance. consumer health - Measles.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2002 May 1;13(7):803-13 [11975847.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2002-7 [11567982.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1971-7 [12075059.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2462-9 [12750267.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4919-26 [15256464.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Aug;26(2):432-6 [15296910.001]
  • [Cites] J Infect Dis. 1990 Nov;162(5):1036-42 [2230231.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):291S-295S [9337306.001]
  • [Cites] Diagn Microbiol Infect Dis. 1999 Mar;33(3):147-52 [10092962.001]
  • [Cites] Thorax. 1999 Aug;54(8):707-10 [10413724.001]
  • [Cites] J Virol. 1999 Nov;73(11):9568-75 [10516065.001]
  • [Cites] Chest. 2004 Nov;126(5):1529-39 [15539723.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2287-94 [15961518.001]
  • [Cites] Eur Respir J. 2006 Apr;27(4):817-21 [16585090.001]
  • [Cites] J Virol. 2006 Aug;80(15):7769-74 [16840358.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):177-84 [16642271.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):1-9 [16893591.001]
  • [Cites] J Gen Virol. 2006 Oct;87(Pt 10):2767-79 [16963735.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):114-22 [17164782.001]
  • [Cites] Transfusion. 2006 Dec;46(12):2083-9 [17176319.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Eur J Intern Med. 2008 Jul;19(5):334-9 [18549935.001]
  • [Cites] Exp Oncol. 2008 Jun;30(2):91-5 [18566569.001]
  • [Cites] Clin Vaccine Immunol. 2008 Jul;15(7):1054-9 [18463223.001]
  • [Cites] Prostate. 2009 Jan 1;69(1):82-91 [18973133.001]
  • [Cites] Curr Top Microbiol Immunol. 2009;330:213-41 [19203112.001]
  • [Cites] Mol Ther. 2009 Aug;17(8):1395-403 [19471250.001]
  • [Cites] J Virol. 2000 Sep;74(17):7972-9 [10933705.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):731-8 [10973791.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3746-54 [11389012.001]
  • [Cites] Nat Med. 2002 May;8(5):527-31 [11984600.001]
  • (PMID = 19894113.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / P50 CA116201-010005; United States / NCI NIH HHS / CA / P50 CA116201; United States / NCI NIH HHS / CA / P50CA108961; United States / NCI NIH HHS / CA / CA116201-010005
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Measles Vaccine
  • [Other-IDs] NLM/ NIHMS228888; NLM/ PMC2935656
  •  go-up   go-down


2. Park S, Lee J, Do IG, Jang J, Rho K, Ahn S, Maruja L, Kim SJ, Kim KM, Mao M, Oh E, Kim YJ, Kim J, Choi YL: Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. Sci Rep; 2014;4:3623
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is the most commonly occurring type of soft tissue tumor in children.
  • A peritoneal seeding nodule from the primary tumor, pleural metastases, malignant pleural effusion, and ascites obtained during disease progression, were analyzed.
  • Three of 10 mutations were present in both primary and metastatic tumors, and 3 mutations were detected only in metastatic specimens.
  • Little genetic heterogeneity was observed between primary and metastatic RMS cells.
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 12. Comparative Genomic Hybridization. Disease Progression. Humans. Male. Neoplasm Metastasis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2010 Apr 15;464(7291):999-1005 [20393555.001]
  • [Cites] Pediatr Dev Pathol. 2009 Jul-Aug;12(4):275-83 [18788887.001]
  • [Cites] Cancer Res. 2010 Aug 15;70(16):6497-508 [20663909.001]
  • [Cites] Nature. 2010 Oct 28;467(7319):1114-7 [20981102.001]
  • [Cites] Clin Cancer Res. 2011 Mar 15;17(6):1463-73 [21220470.001]
  • [Cites] Genes Chromosomes Cancer. 2011 Nov;50(11):896-907 [21910158.001]
  • [Cites] J Clin Oncol. 2012 Jan 20;30(3):308-15 [22184391.001]
  • [Cites] Genome Res. 2012 Feb;22(2):196-207 [22183965.001]
  • [Cites] J Clin Oncol. 2012 May 10;30(14):1670-7 [22454413.001]
  • [Cites] J Mol Diagn. 2013 Jan;15(1):51-61 [23246132.001]
  • [Cites] J Clin Oncol. 2013 Jun 1;31(16):2024-8 [23569312.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):275-85 [10534762.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3487-93 [10550146.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):215-23 [11505068.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):377-88 [12124838.001]
  • [Cites] Histopathology. 2002 Nov;41(5):461-7 [12405914.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):571-80 [12879475.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Cell Growth Differ. 1993 Dec;4(12):1065-70 [8117620.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Feb;15(2):89-94 [8834171.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):33-8 [9062578.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4787-94 [15570080.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):183-90 [15895378.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1454-65 [17090187.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6626-36 [17638873.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jun;48(6):455-67 [19235922.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Aug;48(8):661-72 [19422036.001]
  • [Cites] Cancer. 2009 Sep 15;115(18):4218-26 [19536876.001]
  • [Cites] Eur J Cancer. 2010 Jun;46(9):1588-95 [20338746.001]
  • (PMID = 24406431.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC3887377
  •  go-up   go-down


3. Achariyapota V, Chuangsuwanich T, Benjapibal M: Inflammatory Breast Cancer from Metastatic Ovarian Cancer. Case Rep Obstet Gynecol; 2016;2016:3476143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory Breast Cancer from Metastatic Ovarian Cancer.
  • Metastases to the breast from tumors other than breast carcinomas are extremely rare and represent only 0.2-1.3% of all diagnosed malignant breast tumors.
  • Furthermore, while the most common sites for advanced ovarian cancer metastases are the liver, lung, and pleura, metastasis to the breast from a primary ovarian cancer is uncommon and has only been reported in 0.03-0.6% of all breast cancers.
  • Here we describe a case report of a 50-year-old female patient with a rare case of breast metastases from an advanced ovarian cancer, presenting as inflammatory breast cancer.
  • Our observations emphasize the clinical importance of distinguishing between primary and metastatic breast cancer during diagnosis for the purpose of appropriate prognosis and treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27047697.001).
  • [ISSN] 2090-6684
  • [Journal-full-title] Case reports in obstetrics and gynecology
  • [ISO-abbreviation] Case Rep Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4800108
  •  go-up   go-down


Advertisement
4. Verschoor AJ, Gelderblom H: Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clin Sarcoma Res; 2014;4:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series.
  • BACKGROUND: Recently, the phase III PALETTE study introduced pazopanib (Votrient®) as treatment for adult patients with locally advanced or metastatic non-liposarcoma soft tissue sarcoma after prior treatment with doxorubicin and/or ifosfamide.
  • These six patients were treated for malignant peripheral nerve sheath tumour, angiosarcoma, synovial sarcoma, fibromyxomatoid sarcoma, pleomorphic sarcoma and endometrial stromal sarcoma.
  • All six patients had subpleural pulmonary or pleural metastases at the start of pazopanib and the pneumothorax developed during or shortly after treatment with pazopanib and was difficult to treat.
  • This may be related to the fact that there is often pleural metastatic involvement and cystic degeneration due to pazopanib treatment may add to the risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25302110.001).
  • [ISSN] 2045-3329
  • [Journal-full-title] Clinical sarcoma research
  • [ISO-abbreviation] Clin Sarcoma Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4191680
  • [Keywords] NOTNLM ; Adverse event / Pazopanib / Pleural metastases / Pneumothorax / Pulmonary metastases / Soft tissue sarcoma
  •  go-up   go-down


5. Riihimäki M, Hemminki A, Sundquist J, Hemminki K: Patterns of metastasis in colon and rectal cancer. Sci Rep; 2016;6:29765
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of metastasis in colon and rectal cancer.
  • Investigating epidemiology of metastatic colon and rectal cancer is challenging, because cancer registries seldom record metastatic sites.
  • We used a population based approach to assess metastatic spread in colon and rectal cancers.
  • 49,096 patients with colorectal cancer were identified from the nationwide Swedish Cancer Registry.
  • Metastatic sites were identified from the National Patient Register and Cause of Death Register.
  • Rectal cancer more frequently metastasized into thoracic organs (OR = 2.4) and the nervous system (1.5) and less frequently within the peritoneum (0.3).
  • Lung metastases occurred frequently together with nervous system metastases, whereas peritoneal metastases were often listed with ovarian and pleural metastases.
  • Thoracic metastases are almost as common as liver metastases in rectal cancer patients with a low stage at diagnosis.
  • In colorectal cancer patients with solitary metastases the survival differed between 5 and 19 months depending on T or N stage.
  • Metastatic patterns differ notably between colon and rectal cancers.
  • This knowledge should help clinicians to identify patients in need for extra surveillance and gives insight to further studies on the mechanisms of metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27416752.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4945942
  •  go-up   go-down


6. Acencio MM, Puka J, Marchi E, Antonangelo L, Terra RM, Vargas FS, Capelozzi VL, Teixeira LR: A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells. J Transl Med; 2015;13:302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells.
  • BACKGROUND: Malignant pleural effusion resulting mainly from pleural metastases of lung adenocarcinoma has clinical relevance, being a sign of poor prognosis and low life expectancy.
  • Experimental models can mimic the human condition, contributing to advances in current understanding of the mechanisms patients' pleural fluid accumulation and possible therapeutic strategies.
  • METHODS: C57BL/6 mice received intrapleural injection of 0.1, 0.5 or 1.5 × 10(5) LLC cells and survival curve, biochemical and pathological analyses of pleural fluid and tissue were analyzed.
  • CONCLUSION: This study may allow a better understanding the mechanisms involved in the development of malignant pleural effusion and it may be promising in evaluating therapy to avoid recurrence, as the best time to indicate pleurodesis or target therapies.
  • [MeSH-major] Carcinoma, Lewis Lung / pathology. Lung Neoplasms / pathology. Neoplasm Transplantation / methods. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Disease Models, Animal. Humans. Life Expectancy. Male. Mice. Mice, Inbred C57BL. Pleurodesis. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 2001 Aug;18(2):402-19 [11529302.001]
  • [Cites] Respirology. 2002 Sep;7(3):171-91 [12153683.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):21S-49S [12527563.001]
  • [Cites] Eur Respir J. 2003 Mar;21(3):539-44 [12662014.001]
  • [Cites] Respirology. 2004 Jun;9(2):148-56 [15182263.001]
  • [Cites] Eur Respir J. 1989 Apr;2(4):366-9 [2786818.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):47-50 [9815536.001]
  • [Cites] Chest. 2005 Sep;128(3):1790-7 [16162788.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Feb;34(2):142-50 [16210694.001]
  • [Cites] Clin Chest Med. 2006 Jun;27(2):157-80 [16716811.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):1-9 [16893591.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Respiration. 2008;75(2):121-33 [18332619.001]
  • [Cites] Curr Opin Pulm Med. 2009 Jul;15(4):343-52 [19387350.001]
  • [Cites] Curr Opin Pulm Med. 2009 Jul;15(4):380-7 [19436206.001]
  • [Cites] Respirology. 2009 Nov;14(8):1188-93 [19818055.001]
  • [Cites] Mol Cancer. 2010;9:56 [20219102.001]
  • [Cites] Adv Ther. 2010 Jun;27(6):334-47 [20544327.001]
  • [Cites] Thorax. 2010 Aug;65 Suppl 2:ii32-40 [20696691.001]
  • [Cites] Respirology. 2011 Jan;16(1):53-63 [21044230.001]
  • [Cites] Ann Oncol. 2011 Jul;22(7):1507-19 [21536661.001]
  • [Cites] Lung Cancer. 2011 Dec;74(3):392-5 [21616551.001]
  • [Cites] Am J Respir Crit Care Med. 2012 Sep 15;186(6):487-92 [22652027.001]
  • [Cites] J Thorac Oncol. 2012 Oct;7(10):1485-9 [22982649.001]
  • (PMID = 26373420.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4572443
  •  go-up   go-down


7. Soares M, Correia J, Peleteiro MC, Ferreira F: St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol; 2016 Mar;37(3):4053-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.
  • Considering that scarce data are available on disease progression of feline mammary carcinoma (FMC), this study aimed to analyze the clinical, pathological, and immunophenotypic features collected from 61 queens with FMC and to compare the concordance ratios of the expression levels of five molecular markers (ER, PR, fHER2, CK5/6, and Ki-67) between primary tumors (PT) and metastatic lesions.
  • The lung was the organ most frequently affected by metastases, and animals with lung and/or pleural metastases were more likely to display metastases at three or more locations (p = 0.039).
  • A large heterogeneity in protein expression levels was found between PT and paired metastases, with both estrogen and progesterone receptors more likely to be downregulated in metastases.
  • Paired metastases frequently had higher Ki-67 index than PT, whereas fHER2 overexpression was seen in 46 samples (30 %) and CK5/6 expression was found in 50.7 % of metastases (36/71).
  • Results also revealed that disease progression leads to a high percentage of triple negative/basal-like metastases (9/23; 39.1 %) associated with the absence of luminal A subtype in distant metastases (0/23).
  • This study highlights the prognostic importance of immunophenotyping of MC in cats, although the modified protein expression identified in metastases contributes to justify why possible targeted therapies may fail in some animals with metastatic disease.
  • Altogether, the results obtained also demonstrate that FMC can be used as a model to study human breast cancer.
  • [MeSH-minor] Animals. Cat Diseases. Cats. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Kaplan-Meier Estimate. Lymphatic Metastasis. Multivariate Analysis. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2013 Sep 03;13:403 [24004841.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):251-63 [16482564.001]
  • [Cites] Microsc Microanal. 2013 Aug;19(4):876-82 [23718944.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] BMC Vet Res. 2013 Apr 15;9:80 [23587222.001]
  • [Cites] J Comp Pathol. 2014 Feb-Apr;150(2-3):194-7 [24060151.001]
  • [Cites] Mod Pathol. 2004 Dec;17(12):1545-54 [15272277.001]
  • [Cites] Cancer Treat Rev. 2010 May;36(3):206-15 [20060649.001]
  • [Cites] Domest Anim Endocrinol. 2000 Jan;18(1):111-25 [10701768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Anticancer Res. 2014 Mar;34(3):1435-40 [24596391.001]
  • [Cites] J Comp Pathol. 2013 Feb;148(2-3):206-13 [22819018.001]
  • [Cites] Vet Pathol. 2015 Mar;52(2):238-49 [25060990.001]
  • [Cites] Vet Pathol. 2015 Jan;52(1):46-60 [24741029.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Vet Pathol. 2012 Nov;49(6):979-87 [22337774.001]
  • [Cites] Ann Oncol. 2010 Jun;21(6):1254-61 [19858088.001]
  • [Cites] Lancet Oncol. 2010 Feb;11(2):174-83 [20152769.001]
  • [Cites] Ann Oncol. 2013 Sep;24(9):2206-23 [23917950.001]
  • [Cites] Vet Pathol. 2005 Jan;42(1):30-4 [15657269.001]
  • [Cites] Vet Pathol. 2016 Jan;53(1):37-43 [26080833.001]
  • [Cites] J Clin Oncol. 2012 Feb 20;30(6):593-9 [22124109.001]
  • [Cites] Asian Pac J Cancer Prev. 2012;13(4):1111-3 [22799290.001]
  • [Cites] Oncologist. 2012;17(2):172-8 [22267852.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5287-312 [17954709.001]
  • [Cites] BMC Cancer. 2013 Nov 25;13:558 [24274821.001]
  • [Cites] Med Oncol. 2014 Jan;31(1):798 [24307349.001]
  • [Cites] Vet Rec. 2006 Jun 17;158(24):821-4 [16782855.001]
  • [Cites] PLoS One. 2013 Dec 26;8(12):e83673 [24386251.001]
  • [Cites] Breast. 2012 Feb;21(1):50-7 [21865043.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1565-79 [15855655.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):172-80 [19383293.001]
  • [Cites] Vet J. 2012 Jan;191(1):65-71 [21282070.001]
  • [Cites] Breast Cancer Res Treat. 2014 Jun;145(2):503-11 [24771049.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54 [18488249.001]
  • [Cites] J Comp Pathol. 2011 Feb-Apr;144(2-3):170-9 [20880546.001]
  • [Cites] Breast Cancer (Auckl). 2013;7:23-34 [23514931.001]
  • [Cites] Eur J Cancer. 2014 Jan;50(2):277-89 [24269135.001]
  • [Cites] J Clin Pathol. 2013 Jun;66(6):512-6 [23436927.001]
  • [Cites] J Pathol. 2014 Jan;232(1):23-31 [24122263.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):907-12 [15705889.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jul;134(7):e48-72 [20586616.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1499-504 [19299408.001]
  • [Cites] J Clin Oncol. 2013 Nov 1;31(31):3997-4013 [24101045.001]
  • [Cites] Vet J. 2011 Jan;187(1):65-71 [19955006.001]
  • [Cites] BMC Cancer. 2012 Nov 24;12:555 [23176370.001]
  • [Cites] BMC Cancer. 2007 Sep 20;7:179 [17880730.001]
  • (PMID = 26486327.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  • [Keywords] NOTNLM ; Feline mammary carcinoma / Metastatic disease / Molecular classification / Prognostic biomarkers
  •  go-up   go-down


8. Na II, Park JH, Choe du H, Lee JK, Koh JS: Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer. ISRN Oncol; 2011;2011:756265
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer.
  • We performed this retrospective study to assess the association of epidermal growth factor receptor (EGFR) with metastatic presentations in advanced non-small cell lung cancer (NSCLC).
  • When the metastatic sites were analyzed, pleural metastases were associated with a high incidence of EGFR mutations (P = .028).
  • Particularly, pleural metastases with minimal effusion (PMME) were associated with EGFR mutational status (P = .001).
  • EGFR mutations may be associated with different presentations of pleural and N3 nodal metastases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22091430.001).
  • [ISSN] 2090-567X
  • [Journal-full-title] ISRN oncology
  • [ISO-abbreviation] ISRN Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3195961
  •  go-up   go-down


9. Canessa PA, Ferro P, Manta C, Sivori M, Franceschini MC, Fedeli F, Roncella S: Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. Med Oncol; 2013;30(3):649
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.
  • The aim of this study based on the third phase of the architecture of diagnostic research was to assess the sensitivity and specificity of soluble mesothelin-related peptide (SMRP) in pleural exudative effusions (PE) compared to the histology obtained by medical thoracoscopy as the diagnostic gold standard examination.
  • We had 34 mesotheliomas (25 epithelioid and 9 sarcomatoid), 35 pleural metastases, and 35 benign diseases.
  • PE-SMRP were significantly higher in patients with epitheliomorphic mesothelioma (mean ± SD 46.55 ± 44.29 nM) than in patients with sarcomatoid mesothelioma (16.11 ± 25.02 nM; p = 0.061), pleural metastasis (7.52 ± 10.77 nM; p < 0.0001), or benign diseases (5.82 ± 8.86 nM; p < 0.0001).
  • The diagnostic sensitivity and specificity of PE-SMRP for distinguishing mesothelioma from all other causes of pleural effusion, at a cut-off value of 19.6 nM, were 58.8 and 97.1 %, respectively.
  • PE-SMRP higher than the assumed cut-off of 19.6 nM were observed in 18/25 (72.0%) epitheliomorphic mesotheliomas, 2/9 (22.2%) sarcomatoid mesotheliomas, 5/35 (14.3%) pleural metastases, and 1/35 (2.9%) benign diseases.
  • (2) a negative mesothelin does not exclude a malignant disease.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / pathology. Multidrug Resistance-Associated Proteins / metabolism. Pleural Effusion / diagnosis. Pleural Effusion / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 2012 Jul 19;27(2):e99-104 [22653740.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(17):2709-14 [16243515.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Anticancer Res. 2013 Jun;33(6):2707-13 [23749930.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Sep 1;180(5):437-44 [19299498.001]
  • [Cites] Clin Chem Lab Med. 2011 Oct;49(10):1721-6 [21692685.001]
  • [Cites] Clin Cancer Res. 2011 Mar 1;17(5):1181-9 [21177406.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5076-81 [17785560.001]
  • [Cites] Chest. 2004 Dec;126(6):1757-63 [15596670.001]
  • [Cites] Thorax. 2007 Jul;62(7):569-76 [17356060.001]
  • [Cites] Med Oncol. 2013 Jun;30(2):543 [23532816.001]
  • [Cites] Thorax. 2010 Aug;65 Suppl 2:ii54-60 [20696694.001]
  • [Cites] BMJ. 2002 Mar 2;324(7336):539-41 [11872558.001]
  • [Cites] Cancer Invest. 2013 Jan;31(1):43-50 [23249166.001]
  • [Cites] An Med Interna. 2008 Apr;25(4):173-7 [18604333.001]
  • [Cites] Diagn Cytopathol. 2010 Dec;38(12):874-9 [20049969.001]
  • (PMID = 23873013.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCC5 protein, human; 0 / Multidrug Resistance-Associated Proteins
  •  go-up   go-down


10. Baheti AD, Tirumani SH, Sewatkar R, Shinagare AB, Hornick JL, Ramaiya NH, Jagannathan JP: Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients. Br J Radiol; 2015 Feb;88(1046):20140608
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients.
  • OBJECTIVE: To study the appearance of primary and metastatic extremity synovial sarcoma (SS) on cross-sectional imaging.
  • METHODS: In this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study, the imaging features of 78 patients (42 males and 36 females; mean age, 40 years) with primary and metastatic extremity SS on MRI and multidetector CT were reviewed, with baseline MRI of the primary available in 31 patients.
  • Recurrent/metastatic disease developed in 49/78 (63%) patients.
  • Of these, 20/78 (26%) had metastasis at presentation, while the remaining developed metastatic disease at a median interval of 27 months (range, 3-161 months).
  • Pleuropulmonary metastases (46/78) were the most common sites, with most of the metastases being pleural based.
  • On univariate analysis, larger tumour size, the presence of perilesional oedema, intercompartmental extension, the presence of intralesional haemorrhage and bowl of grapes appearance on MRI were associated with a significantly higher incidence of metastatic disease.
  • CONCLUSION: Certain imaging features of primary SS predict the risk of development of metastatic disease.
  • Pleural-based metastases are commonly seen in SSs.
  • ADVANCES IN KNOWLEDGE: Imaging features of primary SS correlate with metastatic disease.
  • Pleural-based metastases are often present in SSs.
  • [MeSH-major] Lung Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pleural Neoplasms / secondary. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Extremities. Female. Follow-Up Studies. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2014 Apr;87(1036):20130719 [24641199.001]
  • [Cites] Br J Radiol. 2008 Apr;81(964):346-56 [18250123.001]
  • [Cites] Radiology. 2014 Jul;272(1):192-201 [24611604.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):525-34 [11208847.001]
  • [Cites] AJR Am J Roentgenol. 2010 Oct;195(4):1026-32 [20858835.001]
  • [Cites] AJR Am J Roentgenol. 2011 Jul;197(1):W37-43 [21700993.001]
  • [Cites] AJR Am J Roentgenol. 2012 Aug;199(2):W208-15 [22826423.001]
  • [Cites] Cancer. 2012 Nov 1;118(21):5339-48 [22517534.001]
  • [Cites] Eur J Cancer. 2012 Dec;48(18):3448-55 [22835783.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):298-303 [23474110.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):140-8 [14716248.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4040-50 [15364967.001]
  • [Cites] Clin Orthop Relat Res. 1981 May;(156):211-5 [6164515.001]
  • [Cites] Clin Orthop Relat Res. 1982 Apr;(164):257-60 [6279348.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1800-8 [3308055.001]
  • [Cites] Ann Surg. 1993 Jan;217(1):72-7 [8424704.001]
  • [Cites] AJR Am J Roentgenol. 1993 Oct;161(4):827-30 [8396848.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1201-8 [8648375.001]
  • [Cites] Skeletal Radiol. 1997 Nov;26(11):674-6 [9428078.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):437-44 [15653701.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1439-45 [15817348.001]
  • [Cites] Radiographics. 2006 Sep-Oct;26(5):1543-65 [16973781.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):314-20 [18286474.001]
  • [Cites] Skeletal Radiol. 2014 May;43(5):615-22 [24496586.001]
  • (PMID = 25431890.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4614246
  •  go-up   go-down






Advertisement